Developer docs
API playgroundTry for free, no card

Search company profiles

Delve Bio

Full company profile

uuid0000mwa

Namestring
Delve Bio
Legal namestring
Delve Bio, Inc.
Websiteurl
delve.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Delve Bio is a privately held, venture-backed biotechnology company that operates a metagenomic next-generation sequencing (mNGS) diagnostic platform focused on infectious disease. The company was founded in 2023 by a group of academic researchers from UCSF, the Broad Institute, and Harvard — including Joe DeRisi, Charles Chiu, Michael Wilson, Pardis Sabeti, and Matthew Meyerson — and is built on an exclusive license to UCSF's mNGS technology. Its flagship commercial product, Delve Detect, is a laboratory-developed test that sequences all DNA and RNA in a cerebrospinal fluid sample and identifies bacteria, viruses, fungi, and parasites against a curated database of more than 68,000 species, delivering results in 48 hours from sample receipt. The underlying Delve Decide platform handles bioinformatics pipeline, taxonomic classification, and clinical interpretation, and every test is paired with expert consultation through the Clinical Microbial Sequencing Board. Delve Bio's headquarters is in Boston, Massachusetts, and the company holds CLIA certification and CAP accreditation, with FDA Breakthrough Device designation for its mNGS assays.

Delve Bio generates revenue on a per-test basis as a CLIA-certified laboratory, with hospitals and reference laboratories ordering Delve Detect directly and submitting samples via a free Sample Transfer Kit and a Salesforce-integrated online portal. Pricing is quote-based and not publicly disclosed; payment terms are advance or net 30 days, with multi-year contracts and the option to adjust pricing on 60 days' written notice. Go-to-market is a direct enterprise sales model with Clinical Account Executives covering defined U.S. territories (Northeast, Mid-Atlantic, Midwest, Southwest), supplemented by a partnership with Broad Clinical Labs (a wholly owned Broad Institute subsidiary) for sequencing capacity. Customers include hospital laboratories, infectious disease specialists, neurology departments, and reference labs managing patients with suspected meningitis or encephalitis; the company cites a 60% diagnostic gap in CNS infections and clinical evidence showing that 22% greater diagnostic yield, 64% of microbiological tests avoidable with early mNGS, and 54% of mNGS-only diagnoses resulting in treatment changes. The company has raised $35 million in a Series A led by Perceptive Xontogeny Venture Fund II with Section 32 and Google Ventures, and was recognized in BioSpace's NextGen Class of 2024.

Short descriptiontext

Delve Bio is a clinical metagenomics company that operates a CLIA-certified laboratory offering Delve Detect, an mNGS test that identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid for meningitis and encephalitis diagnosis. It serves U.S. hospitals, neurology and infectious disease departments, and reference laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
metagenomic sequencing diagnostics, infectious disease testing, clinical laboratory services, pathogen detection, meningitis encephalitis diagnosis
Industry3 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Infectious Disease Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Diagnostic Testing Services
TypeTransaction Fee
Description

Delve Bio operates as a CLIA-certified laboratory offering mNGS diagnostic testing services. Customers (hospitals, laboratories) submit cerebrospinal fluid samples for metagenomic sequencing analysis. The company performs the assay, analyzes results through its proprietary Delve Decide platform, and delivers clinical reports to ordering physicians. Revenue is generated per test performed, with pricing in U.S. dollars adjusted on 60 days advance written notice. Sample transfer tubes are provided free of charge for sample collection and shipment.

delve.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Laboratory-developed test (LDT) pricing - quote-based
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; quote-based. Prices in U.S. dollars, adjusted on 60 days advance written notice. Sample Transfer Tubes provided free. Payment terms: advance or net 30 days from invoice date.

delve.bio
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Delve Detect
Description

Metagenomic sequencing (mNGS) test for detecting bacteria, viruses, fungi, and parasites in cerebrospinal fluid for meningitis and encephalitis diagnosis.

delve.bio
+1 more record
Core offering1 text field

Delve Bio is a CLIA-certified, CAP-accredited clinical laboratory that provides metagenomic next-generation sequencing (mNGS) diagnostic testing for infectious diseases, with a flagship test (Delve Detect) that sequences all nucleic acids in cerebrospinal fluid to identify bacteria, viruses, fungi, and parasites for diagnosis of meningitis and encephalitis. The service is powered by the proprietary Delve Decide bioinformatics platform and curated pathogen database of more than 68,000 species, with results delivered in 48 hours from sample receipt and bundled with expert clinical consultation through its Clinical Microbial Sequencing Board.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 22% greater diagnostic yield compared to all other infectious disease tests combined
+8 more records
Product overview1 text field

Delve Bio offers a unified product portfolio anchored by its flagship mNGS diagnostic test, Delve Detect, which is powered by the proprietary Delve Decide bioinformatics platform. The portfolio consists of Delve Detect (the core laboratory-developed test for meningitis and encephalitis using cerebrospinal fluid), Delve Decide (the underlying bioinformatics pipeline, curated pathogen database of 68,000+ species, and clinical interpretation software), and a supporting ecosystem of sample collection and submission tools including the Delve Sample Transfer Kit and the Delve Bio Portal for online ordering and report access. Expert clinical consultation is bundled into every test through the Clinical Microbial Sequencing Board. The Delve Detect Cost Calculator provides an educational tool for institutions to model clinical utility.

Product and service5 records
1Delve Detect
CategoryLaboratory Diagnostic Testing
Description

A metagenomic next-generation sequencing (mNGS) laboratory-developed test that detects bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF) for diagnosis of meningitis and encephalitis. Delivers results in 48 hours from sample receipt with 22% greater diagnostic yield than traditional testing. Requires only 1mL of CSF shipped at room temperature.

2Delve Decide
CategoryBioinformatics Platform
Description

The proprietary bioinformatics platform powering Delve Bio's metagenomic testing. Includes a curated pathogen database of more than 68,000 unique species, preprocessing filtering and human host background subtraction, taxonomic classification, and automated sequence matching for identifying bacteria, fungi, viruses, and parasites.

3Delve Sample Transfer Kit
CategorySample Collection Supplies
Description

A free sample transfer kit containing tubes with proprietary stabilization buffer, aliquoted pipettes, safety bags, and packaging for overnight shipping of cerebrospinal fluid samples at room temperature. The stabilization buffer deactivates potential pathogens and stabilizes nucleic acids for up to 1 month at room temperature after transfer.

4Delve Bio Portal
CategoryCustomer Portal
Description

A web-based customer portal through which clinicians and laboratories submit orders for Delve Detect, access and download clinical reports, and manage their accounts and authorized users.

5Clinical Microbial Sequencing Board
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-09
Description

Delve Bio partnered with Broad Clinical Labs, a CLIA-licensed and CAP-accredited, wholly owned subsidiary of the Broad Institute of MIT and Harvard, for sample processing and sequencing services. Broad Labs brings over three decades of experience at the cutting edge of genomic research and application.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive licensee of UCSF's metagenomic sequencing (mNGS) technology. Delve Bio is the exclusive provider of the UCSF mNGS test. Multiple co-founders (Joe DeRisi, Charles Chiu, Michael Wilson, Pardis Sabeti) are affiliated with UCSF. Collaborative research published on clinical utility of mNGS for CNS infections.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Delve Bio co-founder Joe DeRisi serves as President of Chan Zuckerberg Biohub SF. Strategic research collaboration and academic partnership leveraging Biohub expertise in infectious disease research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Karius is the leading commercial blood-based mNGS infectious disease diagnostic, directly competing with Delve's CSF test. Both companies offer hypothesis-free sequencing-based pathogen detection to hospitals, with Karius currently ahead in commercial traction and blood-sample adoption.

2IDbyDNA (acquired by Illumina)
TypeDirect peer
Description

IDbyDNA developed a metagenomics-based infectious disease testing platform analogous to Delve's, and was acquired by Illumina in 2022. Delve's CCO Jeff Field was previously CCO at IDbyDNA. Closely comparable in technology and target market.

TypeEmerging player
Description

Day Zero Diagnostics is an emerging sepsis diagnostics company combining whole-genome sequencing with AI-based pathogen ID and antibiotic resistance prediction. Overlapping technology category (NGS + bioinformatics) for infectious disease with potential to expand into CNS.

TypeDirect peer
Description

Clear Labs is a NGS-based pathogen detection company (initially food safety, now expanding into clinical microbiology). Delve's CCO Jeff Field was previously CCO at Clear Labs. Comparable in core NGS microbiology technology and clinical lab business model.

TypeBroad incumbent
Description

bioMérieux is a global leader in in vitro diagnostics and clinical microbiology, including the BioFire FilmArray syndromic panels that compete with Delve for CNS infection diagnosis. A broad incumbent whose existing hospital relationships and reimbursement infrastructure could be leveraged to challenge Delve.

TypeBroad incumbent
Description

QIAGEN is a major molecular diagnostics and sample-prep technology provider whose QIAstat-Dx syndromic panels compete in CNS infection diagnosis. Comparable in serving the same clinical microbiology hospital buyers.

TypeEmerging player
Description

Adaptive Biotechnologies applies immune repertoire sequencing to infectious disease and immune-mediated disease diagnosis. Pardis Sabeti (Delve co-founder) is an Adaptive co-founder. Adjacent in next-gen sequencing approach to clinical diagnostics.

TypeEmerging player
Description

Sherlock Biosciences uses CRISPR-based molecular diagnostics for infectious disease detection, founded by Delve co-founder Pardis Sabeti. Adjacent technology category (novel molecular diagnostics) and shared founder network; potentially complementary.

TypeBroad incumbent
Description

Roche Diagnostics is a global leader in molecular and clinical lab diagnostics, owning Foundation Medicine. Sudeb Dalai (Delve VP Medical Affairs) held roles at Roche Diagnostics. A broad incumbent with potential to enter the mNGS space or partner with/compete against Delve.

TypeEmerging player
Description

Arc Bio (formerly Pathogenomix) is an early-stage mNGS-based pathogen detection company focused on clinical infectious disease. Comparable in technology approach (metagenomic NGS for pathogen ID) and target market (hospitals/clinical labs).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Delve Bio

Infectious Disease Diagnosticsdelve.bio

Delve Bio is a clinical metagenomics company that operates a CLIA-certified laboratory offering Delve Detect, an mNGS test that identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid for meningitis and encephalitis diagnosis. It serves U.S. hospitals, neurology and infectious disease departments, and reference laboratories.

What Delve Bio does

Delve Bio is a privately held, venture-backed biotechnology company that operates a metagenomic next-generation sequencing (mNGS) diagnostic platform focused on infectious disease. The company was founded in 2023 by a group of academic researchers from UCSF, the Broad Institute, and Harvard — including Joe DeRisi, Charles Chiu, Michael Wilson, Pardis Sabeti, and Matthew Meyerson — and is built on an exclusive license to UCSF's mNGS technology. Its flagship commercial product, Delve Detect, is a laboratory-developed test that sequences all DNA and RNA in a cerebrospinal fluid sample and identifies bacteria, viruses, fungi, and parasites against a curated database of more than 68,000 species, delivering results in 48 hours from sample receipt. The underlying Delve Decide platform handles bioinformatics pipeline, taxonomic classification, and clinical interpretation, and every test is paired with expert consultation through the Clinical Microbial Sequencing Board. Delve Bio's headquarters is in Boston, Massachusetts, and the company holds CLIA certification and CAP accreditation, with FDA Breakthrough Device designation for its mNGS assays.

Delve Bio generates revenue on a per-test basis as a CLIA-certified laboratory, with hospitals and reference laboratories ordering Delve Detect directly and submitting samples via a free Sample Transfer Kit and a Salesforce-integrated online portal. Pricing is quote-based and not publicly disclosed; payment terms are advance or net 30 days, with multi-year contracts and the option to adjust pricing on 60 days' written notice. Go-to-market is a direct enterprise sales model with Clinical Account Executives covering defined U.S. territories (Northeast, Mid-Atlantic, Midwest, Southwest), supplemented by a partnership with Broad Clinical Labs (a wholly owned Broad Institute subsidiary) for sequencing capacity. Customers include hospital laboratories, infectious disease specialists, neurology departments, and reference labs managing patients with suspected meningitis or encephalitis; the company cites a 60% diagnostic gap in CNS infections and clinical evidence showing that 22% greater diagnostic yield, 64% of microbiological tests avoidable with early mNGS, and 54% of mNGS-only diagnoses resulting in treatment changes. The company has raised $35 million in a Series A led by Perceptive Xontogeny Venture Fund II with Section 32 and Google Ventures, and was recognized in BioSpace's NextGen Class of 2024.

Delve Bio firmographics

Firmographics
Name
Delve Bio
Legal name
Delve Bio, Inc.
Website
https://delve.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Delve Bio is a clinical metagenomics company that operates a CLIA-certified laboratory offering Delve Detect, an mNGS test that identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid for meningitis and encephalitis diagnosis. It serves U.S. hospitals, neurology and infectious disease departments, and reference laboratories.
Ownership category
akta.pro rank

Delve Bio industry classification

Industry
Product category
Infectious Disease Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Metagenomic sequencing diagnostics
  • Infectious disease testing
  • Clinical laboratory services
  • Pathogen detection
  • Meningitis encephalitis diagnosis

Where Delve Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Delve Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Laboratory Diagnostic Testing Services: Delve Bio operates as a CLIA-certified laboratory offering mNGS diagnostic testing services. Customers (hospitals, laboratories) submit cerebrospinal fluid samples for metagenomic sequencing analysis. The company performs the assay, analyzes results through its proprietary Delve Decide platform, and delivers clinical reports to ordering physicians. Revenue is generated per test performed, with pricing in U.S. dollars adjusted on 60 days advance written notice. Sample transfer tubes are provided free of charge for sample collection and shipment.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractLaboratory-developed test (LDT) pricing - quote-based

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Delve Bio product offering

Product offering

Core offering

Delve Bio is a CLIA-certified, CAP-accredited clinical laboratory that provides metagenomic next-generation sequencing (mNGS) diagnostic testing for infectious diseases, with a flagship test (Delve Detect) that sequences all nucleic acids in cerebrospinal fluid to identify bacteria, viruses, fungi, and parasites for diagnosis of meningitis and encephalitis. The service is powered by the proprietary Delve Decide bioinformatics platform and curated pathogen database of more than 68,000 species, with results delivered in 48 hours from sample receipt and bundled with expert clinical consultation through its Clinical Microbial Sequencing Board.

Product overview

Delve Bio offers a unified product portfolio anchored by its flagship mNGS diagnostic test, Delve Detect, which is powered by the proprietary Delve Decide bioinformatics platform. The portfolio consists of Delve Detect (the core laboratory-developed test for meningitis and encephalitis using cerebrospinal fluid), Delve Decide (the underlying bioinformatics pipeline, curated pathogen database of 68,000+ species, and clinical interpretation software), and a supporting ecosystem of sample collection and submission tools including the Delve Sample Transfer Kit and the Delve Bio Portal for online ordering and report access. Expert clinical consultation is bundled into every test through the Clinical Microbial Sequencing Board. The Delve Detect Cost Calculator provides an educational tool for institutions to model clinical utility.

Differentiator

Problem solved

Functional benefit

Brands

  • Delve Detect: Metagenomic sequencing (mNGS) test for detecting bacteria, viruses, fungi, and parasites in cerebrospinal fluid for meningitis and encephalitis diagnosis.
  • Delve Decide

Products and services

  • Delve Detect A metagenomic next-generation sequencing (mNGS) laboratory-developed test that detects bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF) for diagnosis of meningitis and encephalitis. Delivers results in 48 hours from sample receipt with 22% greater diagnostic yield than traditional testing. Requires only 1mL of CSF shipped at room temperature.
  • Delve Decide The proprietary bioinformatics platform powering Delve Bio's metagenomic testing. Includes a curated pathogen database of more than 68,000 unique species, preprocessing filtering and human host background subtraction, taxonomic classification, and automated sequence matching for identifying bacteria, fungi, viruses, and parasites.
  • Delve Sample Transfer Kit A free sample transfer kit containing tubes with proprietary stabilization buffer, aliquoted pipettes, safety bags, and packaging for overnight shipping of cerebrospinal fluid samples at room temperature. The stabilization buffer deactivates potential pathogens and stabilizes nucleic acids for up to 1 month at room temperature after transfer.
  • Delve Bio Portal A web-based customer portal through which clinicians and laboratories submit orders for Delve Detect, access and download clinical reports, and manage their accounts and authorized users.
  • Clinical Microbial Sequencing Board

Quantifiable outcome

  • 22% greater diagnostic yield compared to all other infectious disease tests combined
  • +8 more outcomes

Companies that use Delve Bio

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles2 records

Delve Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Delve Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Broad Clinical LabscoreTechnology or Integration · 9 October 2024Delve Bio partnered with Broad Clinical Labs, a CLIA-licensed and CAP-accredited, wholly owned subsidiary of the Broad Institute of MIT and Harvard, for sample processing and sequencing services. Broad Labs brings over three decades of experience at the cutting edge of genomic research and application.
  • University of California San Francisco (UCSF)coreStrategic or Co-development PartnerExclusive licensee of UCSF's metagenomic sequencing (mNGS) technology. Delve Bio is the exclusive provider of the UCSF mNGS test. Multiple co-founders (Joe DeRisi, Charles Chiu, Michael Wilson, Pardis Sabeti) are affiliated with UCSF. Collaborative research published on clinical utility of mNGS for CNS infections.
  • Chan Zuckerberg BiohubcoreStrategic or Co-development PartnerDelve Bio co-founder Joe DeRisi serves as President of Chan Zuckerberg Biohub SF. Strategic research collaboration and academic partnership leveraging Biohub expertise in infectious disease research.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Delve Bio competitors and assessment

Company assessment

Direct peers

  • Karius: Karius is the leading commercial blood-based mNGS infectious disease diagnostic, directly competing with Delve's CSF test. Both companies offer hypothesis-free sequencing-based pathogen detection to hospitals, with Karius currently ahead in commercial traction and blood-sample adoption.
  • IDbyDNA (acquired by Illumina): IDbyDNA developed a metagenomics-based infectious disease testing platform analogous to Delve's, and was acquired by Illumina in 2022. Delve's CCO Jeff Field was previously CCO at IDbyDNA. Closely comparable in technology and target market.
  • Clear Labs: Clear Labs is a NGS-based pathogen detection company (initially food safety, now expanding into clinical microbiology). Delve's CCO Jeff Field was previously CCO at Clear Labs. Comparable in core NGS microbiology technology and clinical lab business model.

Emerging players

  • Day Zero Diagnostics: Day Zero Diagnostics is an emerging sepsis diagnostics company combining whole-genome sequencing with AI-based pathogen ID and antibiotic resistance prediction. Overlapping technology category (NGS + bioinformatics) for infectious disease with potential to expand into CNS.
  • Adaptive Biotechnologies: Adaptive Biotechnologies applies immune repertoire sequencing to infectious disease and immune-mediated disease diagnosis. Pardis Sabeti (Delve co-founder) is an Adaptive co-founder. Adjacent in next-gen sequencing approach to clinical diagnostics.
  • Sherlock Biosciences: Sherlock Biosciences uses CRISPR-based molecular diagnostics for infectious disease detection, founded by Delve co-founder Pardis Sabeti. Adjacent technology category (novel molecular diagnostics) and shared founder network; potentially complementary.
  • Arc Bio (formerly Pathogenomix): Arc Bio (formerly Pathogenomix) is an early-stage mNGS-based pathogen detection company focused on clinical infectious disease. Comparable in technology approach (metagenomic NGS for pathogen ID) and target market (hospitals/clinical labs).

Broad incumbents

  • bioMérieux: bioMérieux is a global leader in in vitro diagnostics and clinical microbiology, including the BioFire FilmArray syndromic panels that compete with Delve for CNS infection diagnosis. A broad incumbent whose existing hospital relationships and reimbursement infrastructure could be leveraged to challenge Delve.
  • QIAGEN: QIAGEN is a major molecular diagnostics and sample-prep technology provider whose QIAstat-Dx syndromic panels compete in CNS infection diagnosis. Comparable in serving the same clinical microbiology hospital buyers.
  • Roche Diagnostics: Roche Diagnostics is a global leader in molecular and clinical lab diagnostics, owning Foundation Medicine. Sudeb Dalai (Delve VP Medical Affairs) held roles at Roche Diagnostics. A broad incumbent with potential to enter the mNGS space or partner with/compete against Delve.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Delve Bio social profiles

Digital presence

Delve Bio compliance and trust

Trust signal

Compliance4 records

Delve Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Delve Bio leadership team

Management profile

Number of profiles

Profiles17 records

Delve Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Delve Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Delve Bio

What does Delve Bio do?

Delve Bio is a CLIA-certified, CAP-accredited clinical laboratory that provides metagenomic next-generation sequencing (mNGS) diagnostic testing for infectious diseases, with a flagship test (Delve Detect) that sequences all nucleic acids in cerebrospinal fluid to identify bacteria, viruses, fungi, and parasites for diagnosis of meningitis and encephalitis. The service is powered by the proprietary Delve Decide bioinformatics platform and curated pathogen database of more than 68,000 species, with results delivered in 48 hours from sample receipt and bundled with expert clinical consultation through its Clinical Microbial Sequencing Board.

Is Delve Bio a public or private company?

Delve Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Delve Bio founded?

Delve Bio was founded in 2023. It employs 11 to 50 people.

Where is Delve Bio based?

Delve Bio is headquartered in Boston, United States, in the North America region.

How does Delve Bio make money?

One revenue line is on record: laboratory Diagnostic Testing Services.

Who are Delve Bio's main competitors?

Direct peers on record are Karius, IDbyDNA (acquired by Illumina) and Clear Labs. Emerging players are Day Zero Diagnostics, Adaptive Biotechnologies, Sherlock Biosciences and Arc Bio (formerly Pathogenomix). Broad incumbents are bioMérieux, QIAGEN and Roche Diagnostics.

Does Delve Bio have an API?

No public API is recorded for Delve Bio.

What industry is Delve Bio in?

Delve Bio's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageDelve Bio Expands Metagenomic Infectious Disease Testing with Launch of Delve Detect Plasma at IDWeek 2026Delve Bio announced the launch of Delve Detect Plasma at IDWeek 2026, expanding its metagenomic testing to blood samples. The test detects over 68,000 pathogens with next-day results, following Delve Detect CSF. The company will present three studies on neuroinvasive arboviruses, enterovirus, and astrovirus.Business Wire BlogDelve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing FailsDelve Bio will present data on its mNGS test Delve Detect at the AAN 2026 Annual Meeting, showing it identifies pathogens missed by standard testing. A case study described a toddler with negative HSV testing who improved after Delve Detect identified HSV-1. The company also reports a multicenter case series for ventriculitis and brain abscess.BioSpaceNew Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/EncephalitisResearchers from Columbia University Irving Medical Center presented data at IDWeek 2025 showing that Delve Bio's metagenomic next-generation sequencing platform Delve Detect can streamline the diagnosis of meningitis and encephalitis by detecting both RNA and DNA pathogens with a single test. The analysis of over 80 patients found that early use of mNGS within 48 hours of the first lumbar puncture could have saved over 280 microbiological tests, reduced diagnosis time by over 61 days for fungal infections, and improved diagnostic yield by over 20 percent compared to conventional testing.Business Wire BlogNew Data Show Early Use of Delve Bio’s Metagenomic Testing Can Reduce Need for Conventional Tests and Overall Length of Stay for Patients with Meningitis/EncephalitisDelve Bio announced at IDWeek 2025 that data from Columbia University researchers, analyzed using a modeling framework of more than 80 patients, demonstrated that early use of their metagenomic next-generation sequencing test Delve Detect could have saved over 280 microbiological tests for meningitis/encephalitis patients. The study found that for patients with viral infections, early mNGS use could have reduced over 90 tests and cut diagnosis time by over 150 days, while fungal infection diagnoses could have been made 61 days earlier. Delve Bio CEO Brad Murray stated the platform increases diagnostic yield by over 20 percent, potentially eliminating protracted clinical workups and reducing the testing burden on patients and physicians.BioSpaceNew Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single TestDelve Bio announced that its metagenomic next-generation sequencing test, Delve Detect, can accurately identify viral subtypes for select pathogens through its proprietary bioinformatics pipeline. The company will present these findings at the Pan American Society for Clinical Virology Annual Meeting in Florida on May 8, 2025. This capability aims to streamline patient management for serious central nervous system infections by providing detailed pathogen information from a single test.FinancialContent Business PageDelve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)Delve Bio and Broad Clinical Labs announced a partnership to scale metagenomic sequencing access for neurological infections. Delve Bio's mNGS platform, used for meningitis and encephalitis, will be commercialized with Broad's operations, delivering results in two days. Delve Detect is expected to become more broadly available this fall.Business Wire BlogDelve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)Delve Bio and Broad Clinical Labs announced a partnership to scale metagenomic sequencing access for patients with neurological infections. The collaboration aims to accelerate commercialization, with Delve Detect expected to become more broadly available this fall.Business Wire BlogDelve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System InfectionsDelve Bio and UCSF presented data from a seven-year study of over 4,800 patients, where mNGS testing detected pathogens in 14.4% of samples, including 440 unique species. Nearly 22% of infections were identified by mNGS alone, with higher diagnostic yield than other tests. The company expects its Delve Neuro service to become more widely available later this year.Pulse 2.0Delve Bio: $35 Million Secured For Commercialize Metagenomic Sequencing Platform For Infectious Disease DiagnosisDelve Bio announced $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II, with Section 32 and GV joining. The funds will commercialize its mNGS-based infectious disease test and advance a pipeline of next-generation tests. The company holds an exclusive in-license from UCSF for its mNGS platform.